On Tuesday, UBS upgraded Vipshop to 'buy' from 'neutral', citing the company's earnings resilience despite ongoing challenges in the e-commerce sector. JPMorgan initiated coverage of Seaport Therapeutics with an 'overweight' rating and a price target of $42, expressing bullish sentiment on the biotech firm.
Citi also initiated coverage of Pershing Square with a 'buy' rating, highlighting its strong attributes as an asset manager and setting a price target of $50. Stifel upgraded Booz Allen Hamilton to 'buy' from 'hold', noting improved fundamentals and low expectations. Additionally, JPMorgan upgraded Cognex, Timken, and Allient to 'overweight', emphasizing their positive exposure to robotics.
Goldman Sachs initiated coverage of Hemab Therapeutics with a 'buy' rating and a price target of $36, citing its potential in treating bleeding disorders. UBS reiterated its 'buy' rating on Micron and raised its price target significantly to $1,626, anticipating a re-rating as AI impacts the memory market.
Rothschild & Co Redburn raised its price target on Nvidia to $300, praising its strong quarterly performance. UBS also initiated coverage of Dave Inc with a 'buy' rating and a $300 price target, forecasting robust growth. Morgan Stanley initiated Avalyn Pharma with a 'buy' rating, highlighting its promising pipeline.
TD Cowen upgraded Lear to 'buy', citing its favorable position in the auto sector. Bank of America raised its price target on Apple to $380, reflecting optimism about AI opportunities. Susquehanna initiated Woodward with a positive outlook, and Melius reiterated its 'buy' rating on Dell, raising its price target to $380.
Barclays upgraded Occidental Petroleum to 'overweight', noting attractive shares, while HSBC upgraded Marvell to 'buy', anticipating revenue growth from the AI-networking sector. These analyst calls indicate a positive outlook for several companies across different industries, which may influence investor decisions and market trends